Form 4 holding
Director, 10%+ Owner
INCYTE CORP
- Security class
- Common Stock
- Shares / value
- 28,205,760
- Estimated value
- $2,654,726,131
- Report date
- 30 Jun 2026
- Price
- $94.12
- Ownership
- Indirect
BAKER BROS. ADVISORS LP
Insider Reports History
- Reporting-owner location
- New York, NY
- Latest reporting-owner signature
-
By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for BAKER BROS. ADVISORS LP
Form 4 holding
Director
BeOne Medicines Ltd.
- Security class
- American Depositary Shares
- Shares / value
- 8,068,411
- Estimated value
- $2,097,786,860
- Report date
- 11 Jun 2026
- Price
- $260.00
- Ownership
- Indirect
Form 4 holding
Director
MADRIGAL PHARMACEUTICALS, INC.
- Security class
- Common Stock
- Shares / value
- 1,948,876
- Estimated value
- $1,020,178,119
- Report date
- 17 Jun 2026
- Price
- $523.47
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
ACADIA PHARMACEUTICALS INC
- Security class
- Common Stock
- Shares / value
- 39,384,587
- Estimated value
- $876,700,906
- Report date
- 29 May 2026
- Price
- $22.26
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Kymera Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 7,955,916
- Estimated value
- $684,208,776
- Report date
- 11 Dec 2025
- Price
- $86.00
- Ownership
- Indirect
Form 4 holding
Director
Denali Therapeutics Inc.
- Security class
- $0.01 Prefunded Warrants
- Shares / value
- 25,996,310
- Estimated value
- $454,675,461
- Report date
- 11 Dec 2025
- Price
- $17.49
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Kymera Therapeutics, Inc.
- Security class
- Prefunded Warrants
- Shares / value
- 10,225,962
- Estimated value
- $449,941,305
- Report date
- 30 Jun 2025
- Price
- $44.00
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Former 10% owner
Celcuity Inc.
- Security class
- Common Stock
- Shares / value
- 4,372,852
- Estimated value
- $448,217,330
- Report date
- 14 Jul 2026
- Price
- $102.50
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Kodiak Sciences Inc.
- Security class
- Common Stock
- Shares / value
- 18,358,772
- Estimated value
- $422,251,756
- Report date
- 18 Dec 2025
- Price
- $23.00
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
BICYCLE THERAPEUTICS PLC
- Security class
- American Depositary Shares
- Shares / value
- 10,018,674
- Estimated value
- $153,412,999
- Report date
- 02 Jan 2026
- Price
- $15.34
- Ownership
- Indirect
Form 4 holding
Director
Kiniksa Pharmaceuticals International, plc
- Security class
- Class A Ordinary Shares
- Shares / value
- 2,744,894
- Estimated value
- $132,166,646
- Report date
- 29 May 2026
- Price
- $48.15
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Replimune Group, Inc.
- Security class
- Common Stock
- Shares / value
- 10,116,095
- Estimated value
- $125,641,900
- Report date
- 05 Mar 2025
- Price
- $12.42
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Prelude Therapeutics Inc
- Security class
- Warrants to purchase Common Stock
- Shares / value
- 20,105,994
- Estimated value
- $89,268,602
- Report date
- 21 Apr 2026
- Price
- $4.44
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Denali Therapeutics Inc.
- Security class
- Common Stock
- Shares / value
- 3,422,366
- Estimated value
- $65,709,427
- Report date
- 03 Jun 2026
- Price
- $19.20
- Ownership
- Indirect
Form 4 holding
Director
Immunocore Holdings plc
- Security class
- American Depositary Shares
- Shares / value
- 2,144,060
- Estimated value
- $63,379,057
- Report date
- 17 Mar 2025
- Price
- $29.56
- Ownership
- Indirect
Form 4 holding
Director
BeOne Medicines Ltd.
- Security class
- Ordinary Shares
- Shares / value
- 161,550
- Estimated value
- $47,975,503
- Report date
- 11 Jun 2026
- Price
- $296.97
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Entrada Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 4,691,392
- Estimated value
- $42,564,061
- Report date
- 20 Nov 2025
- Price
- $9.07
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Replimune Group, Inc.
- Security class
- 2026 $0.0001 Prefunded Warrants
- Shares / value
- 2,609,946
- Estimated value
- $31,475,687
- Report date
- 11 Aug 2026
- Price
- $12.06
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
INCYTE CORP
- Security class
- Common Stock
- Shares / value
- 281,190
- Estimated value
- $26,465,602
- Report date
- 30 Jun 2026
- Price
- $94.12
- Ownership
- Direct
Form 4 holding
Director
BeOne Medicines Ltd.
- Security class
- American Depositary Shares
- Shares / value
- 10,418
- Estimated value
- $2,708,680
- Report date
- 11 Jun 2026
- Price
- $260.00
- Ownership
- Direct
Form 4 holding
Director, 10%+ Owner
ACADIA PHARMACEUTICALS INC
- Security class
- Common Stock
- Shares / value
- 102,876
- Estimated value
- $2,290,019
- Report date
- 29 May 2026
- Price
- $22.26
- Ownership
- Direct
Form 4 holding
Former 10% Owner
Atreca, Inc.
- Security class
- Class A common stock
- Shares / value
- 2,971,128
- Estimated value
- $1,195,879
- Report date
- 19 Oct 2023
- Price
- $0.4025
- Ownership
- Indirect
Form 4 holding
Director
Kiniksa Pharmaceuticals International, plc
- Security class
- Class A Ordinary Shares
- Shares / value
- 14,840
- Estimated value
- $714,546
- Report date
- 29 May 2026
- Price
- $48.15
- Ownership
- Direct
Form 4 holding
Former 10% owner
KALA BIO, Inc.
- Security class
- Common Stock
- Shares / value
- 425,006
- Estimated value
- $588,123
- Report date
- 01 Oct 2025
- Price
- $1.38
- Ownership
- Indirect
Form 4 holding
Director, Former 10% Owner
Neurogene Inc.
- Security class
- Common Stock
- Shares / value
- 414,547
- Estimated value
- $287,198
- Report date
- 18 Dec 2023
- Price
- $0.6928
- Ownership
- Indirect
Form 4 holding
Director
BeOne Medicines Ltd.
- Security class
- Ordinary Shares
- Shares / value
- 1
- Estimated value
- $296
- Report date
- 11 Jun 2026
- Price
- $296.97
- Ownership
- Direct
Form 4 holding
Director, Former 10% Owner
Neurogene Inc.
- Security class
- Common Stock
- Shares / value
- 113
- Estimated value
- $78
- Report date
- 18 Dec 2023
- Price
- $0.6928
- Ownership
- Direct
Form 4 holding
Former 10% owner and director
IGM Biosciences, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 14 Aug 2025
- Price
- $1.26
- Ownership
- Indirect
Form 4 holding
Director
DBV Technologies S.A.
- Security class
- First Pre-Funded Warrant
- Shares / value
- 25,005,240
- Estimated value
- Report date
- 27 Mar 2025
- Price
- Ownership
- Indirect
- Underlying class
- Ordinary Shares
- Underlying amount
Form 4 holding
Director
DBV Technologies S.A.
- Security class
- Second Pre-Funded Warrant
- Shares / value
- 25,005,240
- Estimated value
- Report date
- 12 Jan 2026
- Price
- Ownership
- Indirect
- Underlying class
- Ordinary Shares
- Underlying amount
Form 4 holding
10%+ Owner
BELLICUM PHARMACEUTICALS, INC
- Security class
- Warrants (right to buy)
- Shares / value
- 14,217,844
- Estimated value
- Report date
- 22 Nov 2023
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
vTv Therapeutics Inc.
- Security class
- Prefunded Warrants
- Shares / value
- 5,176,974
- Estimated value
- Report date
- 03 Sep 2025
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
SERA PROGNOSTICS, INC.
- Security class
- Common Stock
- Shares / value
- 5,065,736
- Estimated value
- Report date
- 12 Feb 2025
- Price
- Ownership
- Indirect
Form 4 holding
Director
Kiniksa Pharmaceuticals, Ltd.
- Security class
- Class A Common Shares
- Shares / value
- 2,725,689
- Estimated value
- Report date
- 05 Jun 2024
- Price
- Ownership
- Indirect
Form 4 holding
Director, Former 10% Owner
Neurogene Inc.
- Security class
- Prefunded Warrants
- Shares / value
- 2,656,101
- Estimated value
- Report date
- 18 Dec 2023
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
vTv Therapeutics Inc.
- Security class
- Common Warrant
- Shares / value
- 2,400,605
- Estimated value
- Report date
- 03 Sep 2025
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock or Prefunded Warrant
- Underlying amount
Form 4 holding
10%+ Owner
BELLICUM PHARMACEUTICALS, INC
- Security class
- Common Stock
- Shares / value
- 2,168,818
- Estimated value
- Report date
- 22 Nov 2023
- Price
- Ownership
- Indirect
Form 4 holding
Director, Former 10% Owner
Neoleukin Therapeutics, Inc.
- Security class
- Pre-funded Warrants
- Shares / value
- 1,521,176
- Estimated value
- Report date
- 05 Oct 2023
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
vTv Therapeutics Inc.
- Security class
- Common Stock
- Shares / value
- 135,946
- Estimated value
- Report date
- 03 Sep 2025
- Price
- Ownership
- Indirect
Form 4 holding
Director
TScan Therapeutics, Inc.
- Security class
- Non- Qualified Stock Option (right to buy)
- Shares / value
- 67,000
- Estimated value
- Report date
- 20 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
BeiGene, Ltd.
- Security class
- Share Option (Right to Buy)
- Shares / value
- 45,500
- Estimated value
- Report date
- 21 May 2025
- Price
- Ownership
- Indirect
- Underlying class
- Ordinary Shares
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Replimune Group, Inc.
- Security class
- Non-Qualified Stock Option (right to buy)uy)
- Shares / value
- 44,500
- Estimated value
- Report date
- 01 Apr 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Aeglea BioTherapeutics, Inc.
- Security class
- Non-Qualified Stock Option (right to buy)
- Shares / value
- 40,000
- Estimated value
- Report date
- 08 Jun 2021
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
BICYCLE THERAPEUTICS PLC
- Security class
- Share Option (Right to Buy)
- Shares / value
- 38,000
- Estimated value
- Report date
- 02 Jan 2026
- Price
- Ownership
- Indirect
- Underlying class
- American Depositary Shares
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Prelude Therapeutics Inc
- Security class
- Non-Qualified Stock Option (right to buy)
- Shares / value
- 38,000
- Estimated value
- Report date
- 09 Jun 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Kiniksa Pharmaceuticals International, plc
- Security class
- Non- Qualified Share Option (right to buy)
- Shares / value
- 36,474
- Estimated value
- Report date
- 29 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Class A Ordinary Shares
- Underlying amount
Form 4 holding
Director, 10%+ Owner
ACADIA PHARMACEUTICALS INC
- Security class
- Non- Qualified Stock Option (right to buy)
- Shares / value
- 32,008
- Estimated value
- Report date
- 29 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Denali Therapeutics Inc.
- Security class
- Non-Qualified Stock Option (right to buy)uy)
- Shares / value
- 31,695
- Estimated value
- Report date
- 03 Jun 2025
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Immunocore Holdings plc
- Security class
- Non-Qualified Share Option (right to buy)
- Shares / value
- 26,198
- Estimated value
- Report date
- 15 May 2025
- Price
- Ownership
- Indirect
- Underlying class
- Ordinary Shares
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Talis Biomedical Corp
- Security class
- Non- Qualified Stock Option (right to buy)
- Shares / value
- 23,685
- Estimated value
- Report date
- 09 Jun 2023
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Prelude Therapeutics Inc
- Security class
- Non- Qualified Stock Option (right to buy)
- Shares / value
- 23,500
- Estimated value
- Report date
- 14 Jun 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Denali Therapeutics Inc.
- Security class
- Non- Qualified Stock Option (right to buy)
- Shares / value
- 19,226
- Estimated value
- Report date
- 03 Jun 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Kodiak Sciences Inc.
- Security class
- Non-Qualified Stock Options (right to buy)
- Shares / value
- 17,731
- Estimated value
- Report date
- 30 Jun 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Kiniksa Pharmaceuticals, Ltd.
- Security class
- Class A Common Shares
- Shares / value
- 14,840
- Estimated value
- Report date
- 05 Jun 2024
- Price
- Ownership
- Direct
Form 4 holding
Director, 10%+ Owner
INCYTE CORP
- Security class
- Non-Qualified Stock Options (right to buy)
- Shares / value
- 6,111
- Estimated value
- Report date
- 08 Jun 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Kymera Therapeutics, Inc.
- Security class
- Non-Qualified Stock Option (right to buy)
- Shares / value
- 6,068
- Estimated value
- Report date
- 24 Jun 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
vTv Therapeutics Inc.
- Security class
- Non-Qualified Stock Option (right to buy)
- Shares / value
- 6,000
- Estimated value
- Report date
- 26 Jun 2026
- Price
- Ownership
- Indirect
- Underlying class
- Class A common stock
- Underlying amount
Form 4 holding
Director
MADRIGAL PHARMACEUTICALS, INC.
- Security class
- Non-Qualified Stock Options (right to buy)
- Shares / value
- 1,532
- Estimated value
- Report date
- 17 Jun 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
DBV Technologies S.A.
- Security class
- BS Warrant
- Shares / value
- 0
- Estimated value
- Report date
- 12 Jan 2026
- Price
- Ownership
- Indirect
- Underlying class
- Second Pre-Funded Warrant
- Underlying amount
Form 4 holding
Director
Immunocore Holdings plc
- Security class
- 2.5% Convertible Senior Notes due 2030
- Shares / value
- 0
- Estimated value
- Report date
- 17 Mar 2025
- Price
- Ownership
- Indirect
- Underlying class
- American Depositary Shares
- Underlying amount
Form 4 holding
Director, 10%+ Owner
INCYTE CORP
- Security class
- Non-Qualified Stock Options
- Shares / value
- 0
- Estimated value
- Report date
- 08 May 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, Former 10% Owner
Seagen Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 14 Dec 2023
- Price
- $229.00
- Ownership
- Direct
Form 4 holding
Director, Former 10% Owner
Seagen Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 14 Dec 2023
- Price
- $229.00
- Ownership
- Indirect
Form 4 holding
Director, Former 10% Owner
Seagen Inc.
- Security class
- Stock Options (right to buy)
- Shares / value
- 0
- Estimated value
- Report date
- 14 Dec 2023
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by BAKER BROS. ADVISORS LP
4
REPL
Replimune Group, Inc.
- Report period
- 11 Aug 2026
- Transactions
- 2
- Transaction value
- +$32,999,987
- Accepted by SEC
- 11 Aug 2026, 17:46
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CELC
Celcuity Inc.
- Report period
- 14 Jul 2026
- Transactions
- 2
- Transaction value
- -$317,750,000
- Accepted by SEC
- 16 Jul 2026, 17:42
- Role
- Former 10% owner
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 30 Jun 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2026, 16:32
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 30 Jun 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2026, 16:31
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
VTVT
vTv Therapeutics Inc.
- Report period
- 26 Jun 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 29 Jun 2026, 16:41
- Role
- Director
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 24 Jun 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 25 Jun 2026, 17:10
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MDGL
MADRIGAL PHARMACEUTICALS, INC.
- Report period
- 17 Jun 2026
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 18 Jun 2026, 16:03
- Role
- Director
- Next action
- Open filing details
4
ONC
BeOne Medicines Ltd.
- Report period
- 11 Jun 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 15 Jun 2026, 16:38
- Role
- Director
- Next action
- Open filing details
4
PRLD
Prelude Therapeutics Inc
- Report period
- 09 Jun 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 10 Jun 2026, 16:44
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 08 Jun 2026
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 10 Jun 2026, 16:41
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
DNLI
Denali Therapeutics Inc.
- Report period
- 03 Jun 2026
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 05 Jun 2026, 16:28
- Role
- Director
- Next action
- Open filing details
4
ACAD
ACADIA PHARMACEUTICALS INC
- Report period
- 29 May 2026
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 02 Jun 2026, 16:32
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KNSA
Kiniksa Pharmaceuticals International, plc
- Report period
- 29 May 2026
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 02 Jun 2026, 16:30
- Role
- Director
- Next action
- Open filing details
4
ONC
BeOne Medicines Ltd.
- Report period
- 22 May 2026
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 27 May 2026, 16:54
- Role
- Director
- Next action
- Open filing details
4
TCRX
TScan Therapeutics, Inc.
- Report period
- 20 May 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 22 May 2026, 16:08
- Role
- Director
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 08 May 2026
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 11 May 2026, 16:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
PRLD
Prelude Therapeutics Inc
- Report period
- 21 Apr 2026
- Transactions
- 2
- Transaction value
- +$9,999,774
- Accepted by SEC
- 22 Apr 2026, 16:15
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
REPL
Replimune Group, Inc.
- Report period
- 01 Apr 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 07 Apr 2026, 21:15
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 31 Mar 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Apr 2026, 16:10
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
DBVT
DBV Technologies S.A.
- Report period
- 12 Jan 2026
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 14 Jan 2026, 16:33
- Role
- Director
- Next action
- Open filing details
4
BCYC
BICYCLE THERAPEUTICS PLC
- Report period
- 02 Jan 2026
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 06 Jan 2026, 17:41
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 31 Dec 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 05 Jan 2026, 16:02
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 18 Dec 2025
- Transactions
- 2
- Transaction value
- +$60,000,008
- Accepted by SEC
- 19 Dec 2025, 16:06
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
DNLI
Denali Therapeutics Inc.
- Report period
- 11 Dec 2025
- Transactions
- 2
- Transaction value
- +$39,977,138
- Accepted by SEC
- 15 Dec 2025, 16:33
- Role
- Director
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 11 Dec 2025
- Transactions
- 2
- Transaction value
- +$172,499,918
- Accepted by SEC
- 11 Dec 2025, 16:19
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TRDA
Entrada Therapeutics, Inc.
- Report period
- 20 Nov 2025
- Transactions
- 4
- Transaction value
- +$261,846
- Accepted by SEC
- 24 Nov 2025, 16:09
- Role
- 10%+ Owner
- Next action
- Open filing details
4
TRDA
Entrada Therapeutics, Inc.
- Report period
- 10 Nov 2025
- Transactions
- 12
- Transaction value
- +$1,352,587
- Accepted by SEC
- 12 Nov 2025, 17:34
- Role
- 10%+ Owner
- Next action
- Open filing details
4
KALA
KALA BIO, Inc.
- Report period
- 30 Sep 2025
- Transactions
- 4
- Transaction value
- -$1,056,722
- Accepted by SEC
- 02 Oct 2025, 16:47
- Role
- Former 10% owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 30 Sep 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Oct 2025, 16:36
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CELC
Celcuity Inc.
- Report period
- 08 Sep 2025
- Transactions
- 4
- Transaction value
- +$9,571,319
- Accepted by SEC
- 10 Sep 2025, 16:06
- Role
- 10%+ Owner
- Next action
- Open filing details
4
VTVT
vTv Therapeutics Inc.
- Report period
- 03 Sep 2025
- Transactions
- 6
- Transaction value
- $0
- Accepted by SEC
- 05 Sep 2025, 16:15
- Role
- Director
- Next action
- Open filing details
4
MDGL
MADRIGAL PHARMACEUTICALS, INC.
- Report period
- 18 Aug 2025
- Transactions
- 26
- Transaction value
- +$36,941,197
- Accepted by SEC
- 20 Aug 2025, 18:12
- Role
- Director
- Next action
- Open filing details
4
MDGL
MADRIGAL PHARMACEUTICALS, INC.
- Report period
- 18 Aug 2025
- Transactions
- 28
- Transaction value
- +$24,979,827
- Accepted by SEC
- 20 Aug 2025, 18:09
- Role
- Director
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 14 Aug 2025
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 18 Aug 2025, 17:39
- Role
- Former 10% owner and director
- Next action
- Open filing details
3
CELC
Celcuity Inc.
- Report period
- 01 Aug 2025
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 01 Aug 2025, 17:46
- Role
- 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 30 Jun 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2025, 17:26
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 30 Jun 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2025, 17:23
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TCRX
TScan Therapeutics, Inc.
- Report period
- 30 Jun 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2025, 17:20
- Role
- Director
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 30 Jun 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2025, 17:08
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 30 Jun 2025
- Transactions
- 4
- Transaction value
- +$57,683,934
- Accepted by SEC
- 30 Jun 2025, 20:15
- Role
- Director
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 25 Jun 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 26 Jun 2025, 21:00
- Role
- Director
- Next action
- Open filing details
4
MDGL
MADRIGAL PHARMACEUTICALS, INC.
- Report period
- 20 Jun 2025
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 24 Jun 2025, 16:38
- Role
- Director
- Next action
- Open filing details
4
PRLD
Prelude Therapeutics Inc
- Report period
- 12 Jun 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2025, 16:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 10 Jun 2025
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 12 Jun 2025, 16:29
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
VTVT
vTv Therapeutics Inc.
- Report period
- 10 Jun 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 12 Jun 2025, 16:28
- Role
- Director
- Next action
- Open filing details
4
KNSA
Kiniksa Pharmaceuticals International, plc
- Report period
- 03 Jun 2025
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 05 Jun 2025, 17:06
- Role
- Director
- Next action
- Open filing details
4
DNLI
Denali Therapeutics Inc.
- Report period
- 03 Jun 2025
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 05 Jun 2025, 17:02
- Role
- Director
- Next action
- Open filing details
3
DNLI
Denali Therapeutics Inc.
- Report period
- 03 Jun 2025
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 05 Jun 2025, 16:57
- Role
- Director
- Next action
- Open filing details
4
ACAD
ACADIA PHARMACEUTICALS INC
- Report period
- 29 May 2025
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 02 Jun 2025, 16:01
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ONC
BeiGene, Ltd.
- Report period
- 21 May 2025
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 22 May 2025, 16:10
- Role
- Director
- Next action
- Open filing details
4
IMCR
Immunocore Holdings plc
- Report period
- 15 May 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 19 May 2025, 16:04
- Role
- Director
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 31 Mar 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Apr 2025, 16:43
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 31 Mar 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Apr 2025, 16:39
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
DBVT
DBV Technologies S.A.
- Report period
- 27 Mar 2025
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 31 Mar 2025, 18:56
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IMCR
Immunocore Holdings plc
- Report period
- 17 Mar 2025
- Transactions
- 6
- Transaction value
- -$126,006,776
- Accepted by SEC
- 19 Mar 2025, 18:40
- Role
- Director
- Next action
- Open filing details
4
REPL
Replimune Group, Inc.
- Report period
- 05 Mar 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 07 Mar 2025, 16:55
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
REPL
Replimune Group, Inc.
- Report period
- 05 Mar 2025
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 07 Mar 2025, 16:52
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ONC
BeiGene, Ltd.
- Report period
- 28 Feb 2025
- Transactions
- 2
- Transaction value
- -$190,535,020
- Accepted by SEC
- 28 Feb 2025, 21:28
- Role
- Director
- Next action
- Open filing details
3
SERA
SERA PROGNOSTICS, INC.
- Report period
- 12 Feb 2025
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 14 Feb 2025, 16:06
- Role
- 10%+ Owner
- Next action
- Open filing details
4
BCYC
BICYCLE THERAPEUTICS PLC
- Report period
- 02 Jan 2025
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 06 Jan 2025, 18:12
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 31 Dec 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 03 Jan 2025, 17:22
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 31 Dec 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 03 Jan 2025, 17:19
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KALA
KALA BIO, Inc.
- Report period
- 30 Dec 2024
- Transactions
- 2
- Transaction value
- +$2,000,000
- Accepted by SEC
- 31 Dec 2024, 16:00
- Role
- 10%+ Owner
- Next action
- Open filing details
4
BCYC
BICYCLE THERAPEUTICS PLC
- Report period
- 13 Dec 2024
- Transactions
- 10
- Transaction value
- +$21,230,385
- Accepted by SEC
- 17 Dec 2024, 18:03
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ONC
BeiGene, Ltd.
- Report period
- 09 Dec 2024
- Transactions
- 4
- Transaction value
- -$194,200,043
- Accepted by SEC
- 10 Dec 2024, 21:25
- Role
- Director
- Next action
- Open filing details
4
KNSA
Kiniksa Pharmaceuticals International, plc
- Report period
- 04 Oct 2024
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 08 Oct 2024, 16:14
- Role
- Director
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 30 Sep 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Oct 2024, 16:14
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 30 Sep 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Oct 2024, 16:11
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 20 Aug 2024
- Transactions
- 3
- Transaction value
- +$105,711,766
- Accepted by SEC
- 22 Aug 2024, 16:03
- Role
- Director
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 28 Jun 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2024, 17:04
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 28 Jun 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2024, 16:54
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 28 Jun 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2024, 16:49
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
KALA
KALA BIO, Inc.
- Report period
- 28 Jun 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 28 Jun 2024, 16:03
- Role
- 10%+ Owner
- Next action
- Open filing details
4
VTVT
vTv Therapeutics Inc.
- Report period
- 25 Jun 2024
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 27 Jun 2024, 17:39
- Role
- Director
- Next action
- Open filing details
4
MDGL
MADRIGAL PHARMACEUTICALS, INC.
- Report period
- 25 Jun 2024
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 27 Jun 2024, 17:03
- Role
- Director
- Next action
- Open filing details
4
TRDA
Entrada Therapeutics, Inc.
- Report period
- 25 Jun 2024
- Transactions
- 2
- Transaction value
- +$49,999,658
- Accepted by SEC
- 26 Jun 2024, 16:53
- Role
- 10%+ Owner
- Next action
- Open filing details
4
BCYC
BICYCLE THERAPEUTICS PLC
- Report period
- 17 Jun 2024
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 20 Jun 2024, 16:05
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
PRLD
Prelude Therapeutics Inc
- Report period
- 14 Jun 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 18 Jun 2024, 16:26
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 12 Jun 2024
- Transactions
- 6
- Transaction value
- -$327,550,980
- Accepted by SEC
- 14 Jun 2024, 16:15
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TCRX
TScan Therapeutics, Inc.
- Report period
- 12 Jun 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 14 Jun 2024, 16:13
- Role
- Director
- Next action
- Open filing details
4
KNSA
Kiniksa Pharmaceuticals, Ltd.
- Report period
- 05 Jun 2024
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 07 Jun 2024, 16:07
- Role
- Director
- Next action
- Open filing details
4
ONC
BeiGene, Ltd.
- Report period
- 05 Jun 2024
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 07 Jun 2024, 16:03
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ACAD
ACADIA PHARMACEUTICALS INC
- Report period
- 29 May 2024
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 31 May 2024, 16:10
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
BCYC
BICYCLE THERAPEUTICS plc
- Report period
- 29 May 2024
- Transactions
- 2
- Transaction value
- +$366,600,001
- Accepted by SEC
- 29 May 2024, 16:22
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IMCR
Immunocore Holdings plc
- Report period
- 28 May 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 29 May 2024, 16:53
- Role
- Director
- Next action
- Open filing details
3
IMCR
Immunocore Holdings plc
- Report period
- 28 May 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 29 May 2024, 16:43
- Role
- Director
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 07 May 2024
- Transactions
- 4
- Transaction value
- +$1,470,300
- Accepted by SEC
- 09 May 2024, 18:25
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TCRX
TScan Therapeutics, Inc.
- Report period
- 19 Apr 2024
- Transactions
- 2
- Transaction value
- +$68,999,030
- Accepted by SEC
- 23 Apr 2024, 16:17
- Role
- Director
- Next action
- Open filing details
4
BCYC
BICYCLE THERAPEUTICS plc
- Report period
- 18 Apr 2024
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 22 Apr 2024, 16:03
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
BCYC
BICYCLE THERAPEUTICS plc
- Report period
- 18 Apr 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 18 Apr 2024, 07:26
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 29 Mar 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 01 Apr 2024, 16:22
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 28 Mar 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 01 Apr 2024, 16:26
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KYMR
Kymera Therapeutics, Inc.
- Report period
- 28 Mar 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 01 Apr 2024, 08:56
- Role
- Director
- Next action
- Open filing details
3
KYMR
Kymera Therapeutics, Inc.
- Report period
- 28 Mar 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 01 Apr 2024, 08:53
- Role
- Director
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 26 Mar 2024
- Transactions
- 8
- Transaction value
- +$3,425,569
- Accepted by SEC
- 28 Mar 2024, 19:04
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MDGL
MADRIGAL PHARMACEUTICALS, INC.
- Report period
- 21 Mar 2024
- Transactions
- 2
- Transaction value
- +$274,999,814
- Accepted by SEC
- 25 Mar 2024, 16:21
- Role
- Director
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 12 Mar 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 14 Mar 2024, 16:36
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
VTVT
vTv Therapeutics Inc.
- Report period
- 05 Mar 2024
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 07 Mar 2024, 16:53
- Role
- Director
- Next action
- Open filing details
3
VTVT
vTv Therapeutics Inc.
- Report period
- 27 Feb 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 07 Mar 2024, 16:50
- Role
- Director
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 29 Dec 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 03 Jan 2024, 18:02
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 29 Dec 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 03 Jan 2024, 17:58
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
NGNE
Neurogene Inc.
- Report period
- 18 Dec 2023
- Transactions
- 8
- Transaction value
- $0
- Accepted by SEC
- 20 Dec 2023, 18:43
- Role
- Director, Former 10% Owner
- Next action
- Open filing details
4
Seagen Inc.
- Report period
- 14 Dec 2023
- Transactions
- 13
- Transaction value
- -$10,248,908,740
- Accepted by SEC
- 18 Dec 2023, 18:46
- Role
- Director, Former 10% Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 13 Dec 2023
- Transactions
- 12
- Transaction value
- +$3,431,464
- Accepted by SEC
- 15 Dec 2023, 17:32
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MDGL
MADRIGAL PHARMACEUTICALS, INC.
- Report period
- 13 Dec 2023
- Transactions
- 24
- Transaction value
- +$22,516,577
- Accepted by SEC
- 14 Dec 2023, 18:10
- Role
- Director
- Next action
- Open filing details
4
PRLD
Prelude Therapeutics Inc
- Report period
- 13 Dec 2023
- Transactions
- 2
- Transaction value
- +$24,999,997
- Accepted by SEC
- 13 Dec 2023, 16:35
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MDGL
MADRIGAL PHARMACEUTICALS, INC.
- Report period
- 12 Dec 2023
- Transactions
- 30
- Transaction value
- +$7,548,616
- Accepted by SEC
- 14 Dec 2023, 18:09
- Role
- Director
- Next action
- Open filing details
4
BELLICUM PHARMACEUTICALS, INC
- Report period
- 22 Nov 2023
- Transactions
- 4
- Transaction value
- +$212
- Accepted by SEC
- 24 Nov 2023, 13:39
- Role
- 10%+ Owner
- Next action
- Open filing details
4
MDGL
MADRIGAL PHARMACEUTICALS, INC.
- Report period
- 21 Nov 2023
- Transactions
- 20
- Transaction value
- +$12,128,340
- Accepted by SEC
- 21 Nov 2023, 18:15
- Role
- Director
- Next action
- Open filing details
4
MDGL
MADRIGAL PHARMACEUTICALS, INC.
- Report period
- 17 Nov 2023
- Transactions
- 30
- Transaction value
- +$11,947,280
- Accepted by SEC
- 21 Nov 2023, 18:14
- Role
- Director
- Next action
- Open filing details
4
MDGL
MADRIGAL PHARMACEUTICALS, INC.
- Report period
- 14 Nov 2023
- Transactions
- 4
- Transaction value
- +$7,809,559
- Accepted by SEC
- 15 Nov 2023, 17:13
- Role
- Director
- Next action
- Open filing details
4
ONC
BeiGene, Ltd.
- Report period
- 14 Nov 2023
- Transactions
- 2
- Transaction value
- -$198,550,000
- Accepted by SEC
- 14 Nov 2023, 17:54
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MDGL
MADRIGAL PHARMACEUTICALS, INC.
- Report period
- 13 Nov 2023
- Transactions
- 30
- Transaction value
- +$15,801,021
- Accepted by SEC
- 15 Nov 2023, 17:12
- Role
- Director
- Next action
- Open filing details
4
Atreca, Inc.
- Report period
- 19 Oct 2023
- Transactions
- 2
- Transaction value
- -$110,582
- Accepted by SEC
- 23 Oct 2023, 16:49
- Role
- Former 10% Owner
- Next action
- Open filing details
4
NGNE
Neoleukin Therapeutics, Inc.
- Report period
- 05 Oct 2023
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 10 Oct 2023, 16:22
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MDGL
MADRIGAL PHARMACEUTICALS, INC.
- Report period
- 03 Oct 2023
- Transactions
- 2
- Transaction value
- +$249,999,821
- Accepted by SEC
- 05 Oct 2023, 16:27
- Role
- Director
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 29 Sep 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 03 Oct 2023, 17:33
- Role
- Director
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 29 Sep 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 03 Oct 2023, 17:32
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
NGNE
Neoleukin Therapeutics, Inc.
- Report period
- 15 Aug 2023
- Transactions
- 12
- Transaction value
- +$1,463,487
- Accepted by SEC
- 17 Aug 2023, 17:08
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 30 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 05 Jul 2023, 17:07
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 30 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 05 Jul 2023, 17:05
- Role
- Director
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 30 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 05 Jul 2023, 17:04
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 26 Jun 2023
- Transactions
- 2
- Transaction value
- +$45,000,000
- Accepted by SEC
- 28 Jun 2023, 17:00
- Role
- Director
- Next action
- Open filing details
4
PRLD
Prelude Therapeutics Inc
- Report period
- 16 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 21 Jun 2023, 16:47
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ONC
BeiGene, Ltd.
- Report period
- 15 Jun 2023
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 20 Jun 2023, 17:34
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MDGL
MADRIGAL PHARMACEUTICALS, INC.
- Report period
- 15 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 20 Jun 2023, 16:10
- Role
- Director
- Next action
- Open filing details
3
MDGL
MADRIGAL PHARMACEUTICALS, INC.
- Report period
- 15 Jun 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 20 Jun 2023, 06:17
- Role
- Director
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 14 Jun 2023
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 16 Jun 2023, 16:02
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TCRX
TScan Therapeutics, Inc.
- Report period
- 13 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 15 Jun 2023, 16:40
- Role
- Director
- Next action
- Open filing details
4
Talis Biomedical Corp
- Report period
- 09 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2023, 16:52
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
NGNE
Neoleukin Therapeutics, Inc.
- Report period
- 08 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 12 Jun 2023, 16:03
- Role
- Director
- Next action
- Open filing details
4
KNSA
Kiniksa Pharmaceuticals, Ltd.
- Report period
- 06 Jun 2023
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 08 Jun 2023, 17:37
- Role
- Director
- Next action
- Open filing details
4
ACAD
ACADIA PHARMACEUTICALS INC
- Report period
- 01 Jun 2023
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 05 Jun 2023, 17:14
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TCRX
TScan Therapeutics, Inc.
- Report period
- 01 Jun 2023
- Transactions
- 2
- Transaction value
- +$74,996,250
- Accepted by SEC
- 02 Jun 2023, 16:00
- Role
- Director
- Next action
- Open filing details
4
Seagen Inc.
- Report period
- 31 May 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Jun 2023, 21:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ACAD
ACADIA PHARMACEUTICALS INC
- Report period
- 22 May 2023
- Transactions
- 18
- Transaction value
- +$23,132,348
- Accepted by SEC
- 24 May 2023, 17:09
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
PRLD
Prelude Therapeutics Inc
- Report period
- 22 May 2023
- Transactions
- 4
- Transaction value
- +$74,998,839
- Accepted by SEC
- 24 May 2023, 16:12
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
BELLICUM PHARMACEUTICALS, INC
- Report period
- 05 May 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 05 May 2023, 16:03
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Seagen Inc.
- Report period
- 01 May 2023
- Transactions
- 9
- Transaction value
- +$642,250
- Accepted by SEC
- 03 May 2023, 16:04
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 04 Apr 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 06 Apr 2023, 16:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 31 Mar 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 04 Apr 2023, 15:59
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 31 Mar 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 04 Apr 2023, 15:57
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 13 Mar 2023
- Transactions
- 4
- Transaction value
- +$909,600
- Accepted by SEC
- 15 Mar 2023, 16:03
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ACAD
ACADIA PHARMACEUTICALS INC
- Report period
- 12 Jan 2023
- Transactions
- 4
- Transaction value
- +$156,600
- Accepted by SEC
- 17 Jan 2023, 15:22
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 30 Dec 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 04 Jan 2023, 15:02
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 30 Sep 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 04 Oct 2022, 16:18
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 30 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 05 Jul 2022, 16:26
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 30 Jun 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 01 Jul 2022, 16:29
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KNSA
Kiniksa Pharmaceuticals, Ltd.
- Report period
- 29 Jun 2022
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 30 Jun 2022, 16:00
- Role
- Director
- Next action
- Open filing details
4
ONC
BeiGene, Ltd.
- Report period
- 22 Jun 2022
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 24 Jun 2022, 16:46
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
PRLD
Prelude Therapeutics Inc
- Report period
- 17 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 22 Jun 2022, 16:06
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 15 Jun 2022
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 17 Jun 2022, 16:53
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
DBVT
DBV Technologies S.A.
- Report period
- 13 Jun 2022
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2022, 17:27
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Talis Biomedical Corp
- Report period
- 10 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2022, 17:29
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ACAD
ACADIA PHARMACEUTICALS INC
- Report period
- 07 Jun 2022
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 09 Jun 2022, 17:24
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 02 Jun 2022
- Transactions
- 12
- Transaction value
- +$4,448,168
- Accepted by SEC
- 06 Jun 2022, 17:08
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TRDA
Entrada Therapeutics, Inc.
- Report period
- 02 Jun 2022
- Transactions
- 6
- Transaction value
- +$260,760
- Accepted by SEC
- 06 Jun 2022, 17:07
- Role
- 10%+ Owner
- Next action
- Open filing details
4
TCRX
TScan Therapeutics, Inc.
- Report period
- 01 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 03 Jun 2022, 16:40
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 25 May 2022
- Transactions
- 16
- Transaction value
- +$2,363,748
- Accepted by SEC
- 27 May 2022, 16:44
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TRDA
Entrada Therapeutics, Inc.
- Report period
- 20 May 2022
- Transactions
- 10
- Transaction value
- +$282,447
- Accepted by SEC
- 24 May 2022, 18:39
- Role
- 10%+ Owner
- Next action
- Open filing details
4
TRDA
Entrada Therapeutics, Inc.
- Report period
- 16 May 2022
- Transactions
- 8
- Transaction value
- +$430,701
- Accepted by SEC
- 18 May 2022, 17:38
- Role
- 10%+ Owner
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 16 May 2022
- Transactions
- 14
- Transaction value
- +$2,696,829
- Accepted by SEC
- 18 May 2022, 17:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Seagen Inc.
- Report period
- 13 May 2022
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 17 May 2022, 16:02
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
NGNE
Neoleukin Therapeutics, Inc.
- Report period
- 12 May 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 16 May 2022, 16:01
- Role
- Director
- Next action
- Open filing details
4
TCRX
TScan Therapeutics, Inc.
- Report period
- 10 May 2022
- Transactions
- 8
- Transaction value
- +$2,559,154
- Accepted by SEC
- 12 May 2022, 16:41
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 01 Apr 2022
- Transactions
- 2
- Transaction value
- +$65,000,001
- Accepted by SEC
- 05 Apr 2022, 16:32
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 31 Mar 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 04 Apr 2022, 16:54
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IGMS
IGM Biosciences, Inc.
- Report period
- 12 Mar 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 15 Mar 2022, 17:11
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 08 Mar 2022
- Transactions
- 14
- Transaction value
- +$28,989,770
- Accepted by SEC
- 10 Mar 2022, 17:02
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Seagen Inc.
- Report period
- 08 Mar 2022
- Transactions
- 4
- Transaction value
- +$702,100
- Accepted by SEC
- 10 Mar 2022, 15:39
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 17 Feb 2022
- Transactions
- 8
- Transaction value
- +$35,734,890
- Accepted by SEC
- 22 Feb 2022, 16:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 15 Feb 2022
- Transactions
- 10
- Transaction value
- +$21,832,153
- Accepted by SEC
- 17 Feb 2022, 16:33
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 10 Feb 2022
- Transactions
- 7
- Transaction value
- +$106,952,404
- Accepted by SEC
- 14 Feb 2022, 16:23
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 27 Jan 2022
- Transactions
- 12
- Transaction value
- +$18,084,687
- Accepted by SEC
- 31 Jan 2022, 16:06
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 21 Jan 2022
- Transactions
- 10
- Transaction value
- +$28,806,796
- Accepted by SEC
- 25 Jan 2022, 16:40
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 31 Dec 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 04 Jan 2022, 15:16
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 15 Dec 2021
- Transactions
- 10
- Transaction value
- +$115,558,900
- Accepted by SEC
- 17 Dec 2021, 17:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
TRDA
Entrada Therapeutics, Inc.
- Report period
- 14 Dec 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 16 Dec 2021, 17:35
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Seagen Inc.
- Report period
- 30 Nov 2021
- Transactions
- 20
- Transaction value
- -$63,396,391
- Accepted by SEC
- 02 Dec 2021, 17:51
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Talis Biomedical Corp
- Report period
- 18 Nov 2021
- Transactions
- 1
- Transaction value
- +$218,250
- Accepted by SEC
- 19 Nov 2021, 15:09
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 30 Sep 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 04 Oct 2021, 16:01
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 29 Sep 2021
- Transactions
- 7
- Transaction value
- +$8,330,440
- Accepted by SEC
- 01 Oct 2021, 16:58
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 15 Sep 2021
- Transactions
- 3
- Transaction value
- +$3,005,281
- Accepted by SEC
- 17 Sep 2021, 18:05
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 07 Sep 2021
- Transactions
- 2
- Transaction value
- +$5,365,227
- Accepted by SEC
- 09 Sep 2021, 18:43
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 17 Aug 2021
- Transactions
- 10
- Transaction value
- +$10,009,957
- Accepted by SEC
- 19 Aug 2021, 17:12
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 11 Aug 2021
- Transactions
- 10
- Transaction value
- +$8,960,623
- Accepted by SEC
- 13 Aug 2021, 19:14
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TCRX
TScan Therapeutics, Inc.
- Report period
- 20 Jul 2021
- Transactions
- 6
- Transaction value
- +$21,375,000
- Accepted by SEC
- 22 Jul 2021, 16:06
- Role
- Director
- Next action
- Open filing details
3
TCRX
TScan Therapeutics, Inc.
- Report period
- 15 Jul 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 15 Jul 2021, 18:10
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 30 Jun 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2021, 16:04
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KNSA
Kiniksa Pharmaceuticals, Ltd.
- Report period
- 29 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 01 Jul 2021, 16:08
- Role
- Director
- Next action
- Open filing details
4
KOD
Kodiak Sciences Inc.
- Report period
- 28 Jun 2021
- Transactions
- 14
- Transaction value
- +$23,656,430
- Accepted by SEC
- 30 Jun 2021, 19:29
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ACAD
ACADIA PHARMACEUTICALS INC
- Report period
- 22 Jun 2021
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 24 Jun 2021, 16:22
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
PRLD
Prelude Therapeutics Inc
- Report period
- 18 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 22 Jun 2021, 17:03
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ONC
BeiGene, Ltd.
- Report period
- 16 Jun 2021
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 21 Jun 2021, 16:12
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
SYRE
Aeglea BioTherapeutics, Inc.
- Report period
- 08 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 10 Jun 2021, 16:31
- Role
- Director
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 26 May 2021
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 28 May 2021, 16:17
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
INCY
INCYTE CORP
- Report period
- 14 May 2021
- Transactions
- 4
- Transaction value
- +$758,800
- Accepted by SEC
- 18 May 2021, 16:25
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Seagen Inc.
- Report period
- 14 May 2021
- Transactions
- 7
- Transaction value
- +$665,700
- Accepted by SEC
- 18 May 2021, 16:23
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
NGNE
Neoleukin Therapeutics, Inc.
- Report period
- 11 May 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 May 2021, 17:23
- Role
- Director
- Next action
- Open filing details